Hyperthermia News
-
Profound Medical to Participate in March Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is scheduled ...
-
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. ...
-
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, to be held virtually ...
-
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical ...
-
Profound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021. The event will consist of ...
-
Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc. (NASDAQ/TSX:AKU) (“Akumin”), a leading ...
-
Profound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, ...
-
Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that it has entered into a ...
-
Profound Medical Receives FDA HDE Approval for Sonalleve
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of ...
-
Profound Medical to Present at the Cantor Virtual Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present ...
-
Profound Medical Present at the Canaccord Genuity 40th Annual Growth Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present ...
-
NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx Thermal Oncology System
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care ...
-
NHTSA unveils campaign to prevent child heatstroke deaths in cars
Nationwide ads urge parents, caregivers to think “Where’s baby? Look before you lock” WASHINGTON – With unseasonably warm temperatures already striking many areas around the country, the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) today announced its first-ever national campaign to prevent child heatstroke deaths in ...
-
NeoTherma Oncology Reports on the Safety and Effectiveness of RF-generated Heat Delivery in Preclinical Animal Studies with the Vectron TTx Thermal Device intended for Treatment of Deep Solid Tumors at Society for Thermal Medicine Annual Meeting
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, reported the results of a pre-clinical porcine study that demonstrated the safe and effective heating of the pancreas with a prototype version of its Vectron TTx device. Key Findings and Conclusions: Safety demonstrated by the absence of injury to skin, internal organs ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you